Evaluation of sarcopenia as a prognostic biomarker in locally advanced head and neck squamous cell carcinoma.
Enes ErulDeniz Can GuvenYakup OzbayAhmet Y AltunbulakAlper KahveciogluFatih ErcanMuhammed F YesilMete T UcdalMustafa CengizGözde YazıcıOguz KuscuNilda Sütay SüslüIbrahim GulluMehmet Ruhi OnurSercan AksoyPublished in: Biomarkers in medicine (2023)
Background: We aimed to evaluate the effect of sarcopenia on survival in head and neck squamous cell carcinoma patients treated with chemoradiotherapy. Materials & methods: Disease-free survival and overall survival were compared according to cervical computed tomography for radiotherapy in 123 sarcopenic and non-sarcopenic patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiotherapy with weekly cisplatin. Results: In multivariate analyses, pretreatment sarcopenia was associated with lower disease-free survival (hazard ratio: 2.60; 95% CI: 1.38-4.87; p = 0.003) and overall survival (hazard ratio: 2.86; 95% CI: 1.40-5.85; p = 0.004). Sarcopenic patients experienced more frequent radiotherapy-related toxicities and platinum-related side effects than non-sarcopenic patients. Conclusion: Sarcopenia could be a potential biomarker to predict prognosis and treatment toxicity in head and neck squamous cell carcinoma.
Keyphrases
- locally advanced
- free survival
- rectal cancer
- squamous cell carcinoma
- neoadjuvant chemotherapy
- end stage renal disease
- computed tomography
- newly diagnosed
- radiation therapy
- ejection fraction
- skeletal muscle
- phase ii study
- magnetic resonance imaging
- early stage
- chronic kidney disease
- peritoneal dialysis
- lymph node
- pet ct
- smoking cessation
- patient reported